Does In Vitro Susceptibility Predict Clinical Outcome in Bacterial Keratitis?

Aiyin Chen, Lalitha Prajna, Muthiah Srinivasan, Rajendran Mahalakshmi, John P. Whitcher, Stephen McLeod, Thomas M. Lietman, Nisha R. Acharya

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Purpose: To determine whether clinical outcomes in bacterial keratitis are associated with antibiotic susceptibility. Design: Retrospective, ancillary study using data and samples from a completed randomized clinical trial. Methods: Forty-two patients were enrolled with culture-confirmed bacterial keratitis at Aravind Eye Hospital in South India. All patients received topical moxifloxacin and were randomized to receive either topical prednisolone phosphate or placebo. Outcomes included time to epithelialization, best spectacle-corrected visual acuity (BSCVA), and infiltrate/scar size at three months. Bacterial isolates were cultured, and minimum inhibitory concentration (MIC) to moxifloxacin was measured using Etests. Multiple linear regression was used to assess the effect of MIC on outcome, adjusting for enrollment characteristics. Results: MIC was associated with three-month infiltrate/scar size: each two-fold increase in MIC was associated with a 0.33-mm average diameter increase in scar size (P = .01). MIC was not associated with three-month BSCVA (P = .71) or time to epithelialization (P = .35). Conclusions: MIC was associated with infiltrate/scar size in bacterial keratitis. An ongoing larger, multicenter trial should provide further information on whether this association is maintained across subgroups of organisms.

Original languageEnglish (US)
JournalAmerican Journal of Ophthalmology
Volume145
Issue number3
DOIs
StatePublished - Jan 1 2008
Externally publishedYes

Fingerprint

Keratitis
Microbial Sensitivity Tests
Cicatrix
Visual Acuity
Multicenter Studies
In Vitro Techniques
India
Linear Models
Randomized Controlled Trials
Retrospective Studies
Placebos
Anti-Bacterial Agents

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Chen, A., Prajna, L., Srinivasan, M., Mahalakshmi, R., Whitcher, J. P., McLeod, S., ... Acharya, N. R. (2008). Does In Vitro Susceptibility Predict Clinical Outcome in Bacterial Keratitis? American Journal of Ophthalmology, 145(3). https://doi.org/10.1016/j.ajo.2007.11.004

Does In Vitro Susceptibility Predict Clinical Outcome in Bacterial Keratitis? / Chen, Aiyin; Prajna, Lalitha; Srinivasan, Muthiah; Mahalakshmi, Rajendran; Whitcher, John P.; McLeod, Stephen; Lietman, Thomas M.; Acharya, Nisha R.

In: American Journal of Ophthalmology, Vol. 145, No. 3, 01.01.2008.

Research output: Contribution to journalArticle

Chen, A, Prajna, L, Srinivasan, M, Mahalakshmi, R, Whitcher, JP, McLeod, S, Lietman, TM & Acharya, NR 2008, 'Does In Vitro Susceptibility Predict Clinical Outcome in Bacterial Keratitis?', American Journal of Ophthalmology, vol. 145, no. 3. https://doi.org/10.1016/j.ajo.2007.11.004
Chen, Aiyin ; Prajna, Lalitha ; Srinivasan, Muthiah ; Mahalakshmi, Rajendran ; Whitcher, John P. ; McLeod, Stephen ; Lietman, Thomas M. ; Acharya, Nisha R. / Does In Vitro Susceptibility Predict Clinical Outcome in Bacterial Keratitis?. In: American Journal of Ophthalmology. 2008 ; Vol. 145, No. 3.
@article{b418089120684f87853716f4242fe118,
title = "Does In Vitro Susceptibility Predict Clinical Outcome in Bacterial Keratitis?",
abstract = "Purpose: To determine whether clinical outcomes in bacterial keratitis are associated with antibiotic susceptibility. Design: Retrospective, ancillary study using data and samples from a completed randomized clinical trial. Methods: Forty-two patients were enrolled with culture-confirmed bacterial keratitis at Aravind Eye Hospital in South India. All patients received topical moxifloxacin and were randomized to receive either topical prednisolone phosphate or placebo. Outcomes included time to epithelialization, best spectacle-corrected visual acuity (BSCVA), and infiltrate/scar size at three months. Bacterial isolates were cultured, and minimum inhibitory concentration (MIC) to moxifloxacin was measured using Etests. Multiple linear regression was used to assess the effect of MIC on outcome, adjusting for enrollment characteristics. Results: MIC was associated with three-month infiltrate/scar size: each two-fold increase in MIC was associated with a 0.33-mm average diameter increase in scar size (P = .01). MIC was not associated with three-month BSCVA (P = .71) or time to epithelialization (P = .35). Conclusions: MIC was associated with infiltrate/scar size in bacterial keratitis. An ongoing larger, multicenter trial should provide further information on whether this association is maintained across subgroups of organisms.",
author = "Aiyin Chen and Lalitha Prajna and Muthiah Srinivasan and Rajendran Mahalakshmi and Whitcher, {John P.} and Stephen McLeod and Lietman, {Thomas M.} and Acharya, {Nisha R.}",
year = "2008",
month = "1",
day = "1",
doi = "10.1016/j.ajo.2007.11.004",
language = "English (US)",
volume = "145",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "3",

}

TY - JOUR

T1 - Does In Vitro Susceptibility Predict Clinical Outcome in Bacterial Keratitis?

AU - Chen, Aiyin

AU - Prajna, Lalitha

AU - Srinivasan, Muthiah

AU - Mahalakshmi, Rajendran

AU - Whitcher, John P.

AU - McLeod, Stephen

AU - Lietman, Thomas M.

AU - Acharya, Nisha R.

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Purpose: To determine whether clinical outcomes in bacterial keratitis are associated with antibiotic susceptibility. Design: Retrospective, ancillary study using data and samples from a completed randomized clinical trial. Methods: Forty-two patients were enrolled with culture-confirmed bacterial keratitis at Aravind Eye Hospital in South India. All patients received topical moxifloxacin and were randomized to receive either topical prednisolone phosphate or placebo. Outcomes included time to epithelialization, best spectacle-corrected visual acuity (BSCVA), and infiltrate/scar size at three months. Bacterial isolates were cultured, and minimum inhibitory concentration (MIC) to moxifloxacin was measured using Etests. Multiple linear regression was used to assess the effect of MIC on outcome, adjusting for enrollment characteristics. Results: MIC was associated with three-month infiltrate/scar size: each two-fold increase in MIC was associated with a 0.33-mm average diameter increase in scar size (P = .01). MIC was not associated with three-month BSCVA (P = .71) or time to epithelialization (P = .35). Conclusions: MIC was associated with infiltrate/scar size in bacterial keratitis. An ongoing larger, multicenter trial should provide further information on whether this association is maintained across subgroups of organisms.

AB - Purpose: To determine whether clinical outcomes in bacterial keratitis are associated with antibiotic susceptibility. Design: Retrospective, ancillary study using data and samples from a completed randomized clinical trial. Methods: Forty-two patients were enrolled with culture-confirmed bacterial keratitis at Aravind Eye Hospital in South India. All patients received topical moxifloxacin and were randomized to receive either topical prednisolone phosphate or placebo. Outcomes included time to epithelialization, best spectacle-corrected visual acuity (BSCVA), and infiltrate/scar size at three months. Bacterial isolates were cultured, and minimum inhibitory concentration (MIC) to moxifloxacin was measured using Etests. Multiple linear regression was used to assess the effect of MIC on outcome, adjusting for enrollment characteristics. Results: MIC was associated with three-month infiltrate/scar size: each two-fold increase in MIC was associated with a 0.33-mm average diameter increase in scar size (P = .01). MIC was not associated with three-month BSCVA (P = .71) or time to epithelialization (P = .35). Conclusions: MIC was associated with infiltrate/scar size in bacterial keratitis. An ongoing larger, multicenter trial should provide further information on whether this association is maintained across subgroups of organisms.

UR - http://www.scopus.com/inward/record.url?scp=39149135531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39149135531&partnerID=8YFLogxK

U2 - 10.1016/j.ajo.2007.11.004

DO - 10.1016/j.ajo.2007.11.004

M3 - Article

C2 - 18207124

AN - SCOPUS:39149135531

VL - 145

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 3

ER -